Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PPM1B | O75688 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13871560 | 1.00 | TYMS (0.46) | TYMSLMNASMN1; SMN2RNASE1TSHR | |
| SCHEMBL5717548 | 1.00 | TYMS (0.46) | TYMSLMNASMN1; SMN2RNASE1TSHR | |
| SCHEMBL13871557 | 0.90 | RNASE1 (0.44) | TYMSLMNASMN1; SMN2RNASE1TSHR | |
| SCHEMBL5717621 | 0.86 | RNASE1 (0.47) | TYMSLMNASMN1; SMN2RNASE1TSHR | |
| SCHEMBL5717714 | 0.86 | RNASE1 (0.47) | TYMSLMNASMN1; SMN2RNASE1TSHR | |
| SCHEMBL6285023 | 0.82 | DCK (0.44) | NT5EALDH1A1HTTNPC1PPM1B | |
| SCHEMBL13871554 | 0.81 | NPC1 (0.39) | RNASE1NT5EALDH1A1HTTNPC1 | |
| SCHEMBL24737129 | 0.80 | RNASE1 (0.55) | LMNARNASE1ALDH1A1HTTNPC1 | |
| SCHEMBL24737131 | 0.80 | RNASE1 (0.55) | LMNARNASE1ALDH1A1HTTNPC1 | |
| SCHEMBL8888637 | 0.79 | UPP1 (0.43) | TYMSLMNASMN1; SMN2RNASE1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105185-A1 | Nucleosides with anti-hepatitis B Virus activity | SCHINAZI RAYMOND F | 2009-04-23 | — | — | US | disclosed |
| US-7468357-B2 | Nucleosides with anti-hepatitis B virus activity | EMORY UNIVERSITY (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1655033-A1 | Nucleosides with anti-hepatitis B virus activity | Emory University (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1124565-B1 | AZIDO DERIVATIVES OF BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NAT RECH SCIENT (FR) | 2006-03-29 | — | — | EP | disclosed |
| EP-1124839-B1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NAT RECH SCIENT (FR) | 2006-01-11 | — | — | EP | disclosed |
| US-20050277616-A1 | Thymine nucleosides with anti-hepatitis B virus activity | Owens, Howard | 2005-12-15 | — | — | US | disclosed |
| US-20020107221-A1 | Nucleosides with anti-hepatitis B virus activity | SCHINAZI RAYMOND F (US) | 2002-08-08 | — | — | US | disclosed |
| US-6407077-B1 | ADMINISTERING B-L-(-2*-AZIDO)-2*,3*-DIDEOXY-5-FLUOROCYTIDINE DERIVATIVE; ACQUIRED IMMUNE DEFICIENCY SYNDROMOE (AIDS) TREATMENT | EMORY UNIVERSITY | 2002-06-18 | — | — | US | disclosed |
| EP-1124839-A2 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2001-08-22 | — | — | EP | disclosed |
| EP-1124565-A1 | AZIDO DERIVATIVES OF BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026225-A2 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| WO-2000025799-A1 | β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2000-05-11 | — | — | WO | disclosed |
| EP-0831852-A1 | NUCLEOSIDES WITH ANTI-HEPATITIS B VIRUS ACTIVITY | EMORY UNIVERSITY (US) | 1998-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107221-A1 | Nucleosides with anti-hepatitis B virus activity | PNP, ADA, TYMP | TYMS 35/4885LMNA 760/4885SMN1; SMN2 2815/4885 |
| US-20090105185-A1 | Nucleosides with anti-hepatitis B Virus activity | PNP, TYMP, SAMHD1 | TYMS 29/4885LMNA 1088/4885SMN1; SMN2 2377/4885 |
| US-20050277616-A1 | Thymine nucleosides with anti-hepatitis B virus activity | TYMP, TYMS, PNP | TYMS 2/4885LMNA 1140/4885SMN1; SMN2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.